Camille S.
- Country
- France
- Department
- Oncologie
Research Overview
- Phase 3 Randomized Study of Perioperative Enfortumab Vedotin and Pembrolizumab Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-Eligible Muscle-Invasive Bladder Cancer
- Phase III Evaluation of Acetylsalicylic Acid and Atorvastatin on Overall Survival in Castration-Resistant Prostate Cancer Patients
- Phase III Randomized Trial of Atezolizumab Plus BCG Versus BCG Alone in High-Risk Non-Muscle Invasive Bladder Cancer Patients
Data & Insights
Has run more than one trial at 60 of 259 partner sites.
Specializations
Bladder Cancer Research
The investigator specializes in various forms of bladder cancer treatment, with particular focus on both muscle-invasive and non-muscle invasive disease states.
- High-risk non-muscle invasive bladder cancer management
- Muscle invasive bladder cancer therapeutics
- Advanced urothelial carcinoma treatment
Research interests include immunotherapy applications and novel combination approaches in bladder cancer treatment.
Prostate Cancer Studies
The investigator conducts research in prostate cancer treatment, focusing on both hormone-sensitive and resistant disease states.
- Castration-resistant prostate cancer therapy
- Metastatic prostate adenocarcinoma management
- Novel therapeutic combinations
Areas of investigation include hormone therapy optimization and innovative treatment approaches for various stages of prostate cancer.
Therapeutic Innovation
The investigator explores innovative treatment combinations across urological cancers.
- Immunotherapy integration
- Maintenance therapy strategies
- Perioperative treatment approaches
Research encompasses multimodal treatment strategies and novel therapeutic combinations in urological oncology.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.